Table 2.
Success rates and IOP reduction with MIGS
| Procedure | Study | Follow-up | IOP baseline (mm Hg) mean ± SD (n, number of eyes) | Postoperative IOP | % IOP reduction | Medications baseline | Medications at last FU |
|---|---|---|---|---|---|---|---|
| iStent combined | Craven9 | 24 | 18.6 ± 3.4 (117) | 17.1 ± 2.9 | 8.1 ± 24.0 | 1.6 ± 0.8 | 0.3 ± 0.6 |
| Arriola-Villalobos10 | 48 | 19.4 ± 1.9 (16) | 16.5 ± 3.6 | 15.2 ± 22.4 | 1.3 ± 0.5 | 0.5 ± 0.6 | |
| Fea11 | 48 | 17.8 ± 2.7 | 15.9 ± 2.3 | 10.7 ± 19.9 | 1.9 ± 0.9 | 0.5 ± 0.8 | |
| 2 iStent combined | Arriola Villalobos (INJECT)12 | 60 | 20.0 ± 3.7 | 16.2 ± 2.3 | 18.9 ± 24.2 | 1.3 ± 0.7 | 1.1 ± 0.8 |
| Solo | |||||||
| • 1 iStent | Katz13 | 18 | 19.8 ± 1.3 (36) | 15.6 ± 1.5 | 21.2 ± 10.2 | 1.7 ± 0.6 | 0.2 ± 0.4 |
| • 2 iStents | 18 | 20.1 ± 1.6 (41) | 13.8 ± 1.3 | 31.3 ± 10.3 | 1.8 ± 0.5 | 0.1 ± 0.4 | |
| • 3 iStents | 18 | 20.4 ± 1.8 (38) | 12.1 ± 1.2 | 40.7 ± 10.7 | 1.5 ± 0.7 | 0.1 ± 0.3 | |
| Hydrus combined | Pfeiffer14 | 24 | 18.9 ± 3.3 (50) | 16.5 ± 2.9 | 12.7 ± 23.7 | 2.0 ± 1.0 | 0.5 ± 1.0 |
| Solo | Gandolfi15 | 24 | 24.0 ± 6.0 (21) | 15.0 ± 3.0 | 37.5 ± 28.0 | 3.1 ± 0.6 | 0.9 ± 0.9 |
| Xen | Widder16 | 8.5 (1–23) | 24.3 ± 6.6 | 16.8 ± 7.6 | 2.6 ± 1.1 | 0.2 ± 0.7 | |
| InnFocus | Battle17 | 36 | 23.8 ± 5.3 | 10.7 ± 3.5 | 55 | 2.4 ± 0.9 | 0.7 ± 1.1 |
| ECP combined | Francis18 | 24 | 18.1 ± 3.0 (80) | 16.0 ± 3.3 | 10 | 2.4 ± 1.0 | 2.0 ± 1.0 |
| Siegel19 | 36 | 17.2 ± 4.8 (261) | 14.6 ± 3.1 | 12.6 ± 1.4 | 1.3 ± 0.6 | 0.2 ± 0.6 | |